Therapeutic Optimization, Biomarker Development, and Emerging Strategies in Kidney Cancer

The 2026 ASCO Genitourinary Cancers Symposium (GU26), held February 26-28 in San Francisco, California, showcased pivotal advances in kidney cancer spanning trial readouts, biomarker research, and emerging therapeutic strategies. Two late-breaking phase III readouts headlined the meeting, both evaluating belzutifan, an oral HIF-2α inhibitor. LITESPARK-022 demonstrated superiority of belzutifan plus pembrolizumab over pembrolizumab alone in the adjuvant high-risk clear cell RCC (ccRCC) setting - a first for any combination in adjuvant solid tumor oncology. LITESPARK-011 established belzutifan plus lenvatinib as a superior post-immunotherapy option over cabozantinib in advanced ccRCC, the first phase III superiority result in this context. Collectively, these results position HIF-2α inhibition as an emerging cornerstone across the RCC treatment continuum. Frontline therapy updates reinforced the durability of immunotherapy-based combinations, with individualized regimen selection - balancing efficacy, toxicity, and patient preferences - emerging as a central principle. In the adjuvant space, patient-reported outcome data from RAMPART added important quality-of-life context. A notable finding was the lack of benefit from adjuvant pembrolizumab in non-clear cell RCC, highlighting the need for dedicated histology-specific trials in this underserved population. Biomarker development and emerging strategies - including radiation as an immune sensitizer and novel mechanistic combinations - pointed toward the field's next frontiers. GU26 signaled a new era of therapeutic sophistication in RCC, with patient selection, biomarker validation, and inclusive trial design as defining priorities ahead.